Next-generation sequencing technologies, microarrays and advances in bio nanotechnology have had an enormous impact on research within a short time frame. This impact appears certain to increase further as many biomedical institutions are now acquiring these prevailing new technologies. Beyond conventional sampling of genome content, wide-ranging applications are rapidly evolving for next-generation sequencing, microarrays and nanotechnology. To date, these technologies have been applied in a variety of contexts, including whole-genome sequencing, targeted re sequencing and discovery of transcription factor binding sites, noncoding RNA expression profiling and molecular diagnostics. This paper thus discusses current applications of nanotechnology, next-generation sequencing technologies and microarrays in biomedical research and highlights the transforming potential these technologies offer.
INTRODUCTION
Over the past four years, there has been a fundamental shift away from the application of automated Sanger sequencing for genome analysis. Prior to this departure, the automated Sanger method had dominated the industry for almost two decades and led to a number of monumental accomplishments, including the completion of the only finished-grade human genome sequence. 1 The automated Sanger method is considered as a 'first-generation' technology, and newer methods are referred to as next-generation sequencing (NGS).
Herein, we present a technical review of current sequencing platform performance and microarrays, to provide guidance on how these technologies work and how they may be applied to important biological questions in biomedical research. We also discuss current progress in bio nanotechnology and the upcoming advances and impacts they are expected to have over the next few years.
NEXT GENERATION SEQUENCING TECHNOLOGY
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Nongyue He was born in 1958. He obtained his B.S. degree and M.Sc. degree from Hunan Normal University, China, and his Ph.D. degree from Nanjing University, China. Then he entered Southeast University and Nanjing Medical University as a post-doc researcher and is a professor in Biomedical Science and Medical Engineering School of Southeast University since 2000. His research interest is focused on biochips and biosensors, functional nanomaterials, controlled drug release and tissue engineering. Currently, he particularly contributes his research to the development of high-throughput bioassay methods and the related devices or instruments. transcriptome sequencing and epigenomics. These research efforts have forged the way in the development of new protocols (both molecular and bioinformatic contexts) and have been instrumental in gaining an understanding of the major strengths and weaknesses of this technology. From a clinical perspective there is great potential for NGS in the management and treatment of human health. Immediate and significant impact will come from either replacement or augmentation of existing technologies for genetic screening purposes. Some striking examples of its clinical use include identification of rare genetic variants associated with monogenic Mendelian disorders [2] [3] [4] and efficient detection of either inherited or somatic mutations in cancer genes. 5 6 As cancer is a genetic disease driven by heritable or somatic mutations, new DNA sequencing technologies
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Applications of Nanotechnology, Next Generation Sequencing and Microarrays in Biomedical Research will have a significant impact on the detection, management and treatment of disease. Next-generation sequencing is enabling worldwide collaborative efforts, such as the International Genome Consortium (ICGC) 7 and The Cancer Genome Atlas (TCGA) project, 8 to catalogue the genomic landscape of thousands of cancer genomes across many disease types. Several early reports from individual studies contributing to these consortia have already been published. [9] [10] [11] These discoveries will ultimately lead to a better understanding of disease pathogenesis, bridging to a new era of molecular pathology and personalized medicine. 12 Sequencing technologies include a number of methods that are grouped broadly as template preparation, sequencing and imaging, and data analysis. These new technologies are based on different principles than the classical Sanger-based method, 13 and they are collectively referred to as either 'next-generation' sequencing, 'high throughput' (or even 'ultrahigh throughput') sequencing, 'ultra-deep' sequencing or 'massively parallel' sequencing. These features are the basis for the current revolution and provide the inspiration to apply sequencing approaches to biological questions that would not have been economically or logistically practical before.
Interesting applications are in the field of ancient DNA research, where next-generation sequencing has been successfully applied to analyze genomes of woolly mammoths 14 and Neanderthals. 15 16 Naturally, next-generation sequencing is also used to decode modern genomes, from bacteria 17 18 and viral isolates 19 20 to James Watson. 21 The latter example illustrates that the power of next-generation sequencing is increasingly exploited to re-sequence strains and individuals for which reference genome sequences are available to sample genomic diversity. Such studies have identified mutations in bacterial strains, 22 23 polymorphisms in worm, 24 structural variation in the human genome 25 and specific alleles involved in cancer. 26 In addition to established analyses of genome sequences, next-generation sequencing is triggering new assays and applications that should greatly advance our understanding of genome function. 27 The principle behind these alternative applications, which have been termed 'sequence census' methods, is simple: complex DNA or RNA samples are directly sequenced to determine their content. With reference genomes available, short sequence reads are sufficient to map their locations (except for repeated regions), and once mapped, millions of sequence hits are simply counted to determine their genomic distribution. This concept is based on previous approaches such as serial analysis of gene expression 28 and massively parallel signature sequencing. 29 Next-generation sequencing, however, delivers much more information at affordable costs, and it is easy to implement for a wider range of applications.
USE OF NEXT GENERATION SEQUENCING TECHNOLOGY ON CANCER GENETICS
Mutation Discovery
The discovery of mutations that determine phenotypes is a fundamental premise of genetic research and will be tremendously facilitated by next-generation sequencing approaches, both for focused and genome-wide discovery. Conventional approaches to focused mutation discovery have used directed PCR to amplify selected genomic regions from individual samples, followed by capillary sequencing, alignment of the resulting sequence traces and algorithmic detection of sequence variants. 30 31 The PCR products can instead be sequenced directly using the Roche (454) sequencer as published by Thomas et al. 32 who showed the high sensitivity of this platform to detect rare variants and to alleviate noisy capillary sequence data resulting from contaminating normal cells in tumor samples.
Defining DNA-Protein Interactions
The nuclear interactions between DNA and proteins that control DNA packaging into histones or DNA transcription into mRNA have traditionally been studied in a locusspecific fashion. These processes are poorly understood in complex organisms in terms of how the genome instructs protein binding in a sequence-or structure dependent context (or both). Moreover, the cognate binding sites are difficult to predict accurately with in silico methods.
Regulatory Protein Binding
An approach, called 'ChIP-seq' was used to discover binding sites for the neuron-restrictive silencer factor (NRSF) transcription factor 33 and for the signal transducer and activator of transcription 1 (STAT1) binding protein 34 in human using the Illumina sequencer. In both studies, previously known binding sites were identified by ChIP-seq analysis, validating the approach and the analytical methods. Both studies also compared their findings with those previously discovered by ChIP-chip, determining that the resolution of ChIP-seq was superior and that fewer replicates and therefore less input DNA were required for these assays. It is likely that ChIP-seq significantly contribute to our understanding of how protein binding sites are regulated in a genome-wide fashion in model organisms and humans.
Exploring Chromatin Packaging
Chromatin packaging-how genomic DNA is packaged into histones-largely determines the availability of genes for transcription; therefore, understanding how DNA is 'packaged' is of great interest. Mikkelsen et al. 35 used the Illumina platform to demonstrate the connection between chromatin packaging and gene expression in several different cell types. They found that changes in chromatin state at specific promoters reflect changes in gene expression for the genes they control. Together these studies established a powerful technological paradigm that ties together data from different genome-wide approaches (e.g., histonespecific ChIP, gene expression) to enable a more comprehensive understanding of the biology of a given cell state and how it transitions into that state.
Discovering Noncoding RNAs
Non coding RNA (ncRNA) describes a broad class of regulatory RNA molecules whose myriad functions continue to be characterized in a variety of model organism systems and in human diseases, such as cancer. 36 Discovering the sequences and hence the genomic locations of ncRNAs is complicated-certain classes of ncRNAs are poorly conserved over evolutionary time; therefore, predicting precursor and processed ncRNA sequences in a genome sequence using in silico-based approaches is of limited use (although several programs exist). Fortunately, the lengths of ncRNAs make next-generation sequencing instruments ideal for genome-wide ncRNA discovery. 37 
CURRENT SECOND GENERATION SEQUENCING PLATFORMS FOR BIOMEDICAL RESEARCH
454 Pyrosequencing
The method amplifies DNA inside water droplets in an oil solution (emulsion PCR), with each droplet containing a single DNA template attached to a single primer-coated bead that then forms a clonal colony. The sequencing machine contains many picolitre-volume wells each containing a single bead and sequencing enzymes. Pyrosequencing uses luciferase to generate light for detection of the individual nucleotides added to the nascent DNA, and the combined data are used to generate sequence read-outs. 38 
Illumina (Solexa) Sequencing
Solexa, now part of Illumina, developed a sequencing technology based on reversible dye-terminators. DNA molecules are first attached to primers on a slide and amplified so that local clonal colonies are formed (bridge amplification). Four types of ddNTPs are added, and nonincorporated nucleotides are washed away. Unlike pyrosequencing, the DNA can only be extended one nucleotide at a time. A camera takes images of the fluorescently labeled nucleotides, then the dye along with the terminal 3 blocker is chemically removed from the DNA, allowing the next cycle. 39 
SOLiD Sequencing
Applied Biosystems' SOLiD technology employs sequencing by ligation. Here, pools of all possible oligonucleotides of fixed lengths are labeled according to the sequenced position. Oligonucleotides are annealed and ligated; the preferential ligation by DNA ligase for matching sequences results in a signal informative of the nucleotide at that position. Before sequencing, the DNA is amplified by emulsion PCR. The resulting bead each containing only copies of the same DNA molecule are deposited on a glass slide. 40 
CURRENT HIGH THROUGHPUT THIRD GENERATION SEQUENCING PLATFORMS FOR BIOMEDICAL RESEARCH
In the previously discussed second generation high throughput-NGS platforms, the principle was based on the emulsion PCR amplification of DNA fragments, to make the light signal strong enough for reliable base detection by the CCD cameras. Although the PCR amplification has revolutionized DNA analysis, but in some instances it may introduce base sequence errors or favor of certain sequences over others, thus changing the relative frequency and abundance of various DNA fragments that existed before amplification. To overcome this, the ultimate miniaturization into the nanoscale and the minimal use of biochemical material, would be achievable if the sequence could be determined directly from a single DNA molecule, without the need for PCR amplification and its potential for distortion of abundance levels. This sequencing from a single DNA molecule is now called as the "third generation of high throughput-next generation sequencing technology." 41 The Current third generation sequencing platforms for biomedical research are:
The principle of SMRT sequencer relies on single molecule real time sequencing by synthesis method provided on the sequencing chip containing thousands of zero-mode waveguides (ZMWs). The sequencing reaction of a DNA fragment is performed by a single DNA polymerase molecule, which is attached to the bottom of each ZMW so that each DNA polymerase resides at the detection zone of ZMW. During the sequencing reaction, the DNA fragment is elongated by DNA polymerase with dNTPs that are fluorescently labeled (each nucleotide is labeled with a fluorophore of different color) at the terminal phosphate moiety. The DNA sequence is determined with CCD array on the basis of fluorescence nucleotide detection, which is performed before nucleotide incorporation, while the labeled dNTP forms a cognate association with the DNA template. The fluorescence pulse is stopped after phosphodiester bond formation, which causes the REVIEW Elingarami et al.
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release of a fluorophore that diffuses out of ZMW. Subsequently, the labeled nucleotide incorporation and detection allow us to determine the DNA sequence. 42 43 
Single Molecule Real Time (RNAP) Sequencer
A different single-molecule DNA sequencing approach, i.e., RNA polymerase (RNAP), has been proposed by Greenleaf and Block 44 in 2006 where the RNAP is attached to one polystyrene bead, whilst the distal end of a DNA fragment is attached to another bead. Each bead is placed in an optical trap and the pair of optical traps levitated the beads. The RNAP interacts with the DNA fragment and the transcriptional motion of RNAP along the template, changes the length of the DNA between the two beads. This leads to displacement of the two beads that can be registered with precision in the Angstrom range, resulting in single-base resolution on a single DNA molecule. By aligning four displacement records, each with a lower concentration of one of the four nucleotides, in a role analogous to the primers used in Sanger sequencing and for calibration using the known sequences flanking to the unknown sequenced fragment, it is possible to deduce the sequence information. The technique demonstrates that the movement of a nucleic acid enzyme and the very sensitive optical trap method, which may allow extraction of sequence information directly from a single DNA molecule. 44 
Nanopore DNA Sequencer
In contrary to all DNA sequencers mentioned above, sequencing a DNA molecule with the Nanopore DNA sequencer is free of nucleotide labeling and detection. This technique was developed from studies on translocation of DNA through various artificial nanopores. The DNA sequencing with Nanopore instrument relies on the converting of electrical signal of nucleotides by passing through a nanopore which is an -hemolysin pore covalently attached with cyclodextrin molecule-the binding site for nucleotides.
The principle of this technique is based on the modulation of the ionic current through the pore as a DNA molecule traverses it, revealing characteristics and parameters (diameter, length and conformation) of the molecule. During the sequencing process, the ionic current that passes through the nanopore is blocked by the nucleotide, i.e., the previously cleaved by exonuclease from a DNA strand that interacts with cyclodextrin. The time period of current block is characteristic for each base and enables the DNA sequence to be determined. However, further improvements and modifications in the technique, for example, increasing the number of parameters measured during the translocation of the DNA enabling single-base resolution, could lead to a rapid nanopore-based DNA sequencing technique. 45 
The Ion Torrent Sequencing Technology
In a recent advancement, the first Post Light TM sequencing technology (Ion Torrent) has been introduced (http: //www. iontorrent.com/). This technology creates a direct connection between the chemical and the digital information, enabling fast, simple, massively scalable sequencing. It utilizes the simple nucleic acid Watson's chemistry to incredibly powerful, proprietary of semiconductor technology-The Moore's law. 46 The principle of Ion Torrent semiconductor technology is based on a well characterized biochemical process, in which a nucleotide is incorporated into a strand of DNA by a polymerase, resulting in a release of hydrogen ion as a byproduct. The technological device uses a high-density array of micromachined wells to perform this biochemical process in a massively parallel way with each well holding a different DNA template.
CURRENT APPLICATION OF NANOTECHNOLOGY IN GENOMICS, PROTEOMICS AND MOLECULAR DIAGNOSTICS
Nanotechnologies on Biochips/DNA Microarrays
Even though microarray/biochip methods employing the detection of specific biomolecular interactions are now an indispensable tool for molecular diagnostics, there are some limitations. DNA microarrays and enzyme-linked immunosorbent assay (ELISA) rely on the labeling of samples with a fluorescent tag-a procedure that is timeconsuming and expensive. Nanotechnologies can provide label-free detection and are being applied to overcome some of the limitations of biochip technology. There are several nanoparticles used in molecular diagnostics. The use of nanoparticles as tags or labels allows for the detection of infectious agents in small sample volumes directly in a very sensitive, specific, and rapid format at lower costs than current in-use technologies. This advance in early detection enables accurate and prompt treatment. The technology strengthens and expands the DNA and protein microarray methods and has applications in genomic analysis, proteomics, and molecular diagnostics. Nanosensors are the new contrivance for detection of biomolecular agents. All these new technologies would have to be evaluated in clinical settings before their full import is appreciated and accepted. According to recent research published in the Journal Biosensors and Bioelectronics, a sensitive and selective biosensor platform suited for SNP type using Fe@Au magnetic nanoparticles (GMNPs) to fabricate bead array is described. This new platform integrates the rapid binding kinetics of magnetic nanoparticles carriers, the multiplexing and encoding capabilities of chips, and tagged array. As a DNA sensor, the biotinylated single-stranded DNA was obtained by asymmetry PCR amplification, and then captured by GMNPs modified with streptavidin to form GMNP-ssDNA complexes without further purification. The complexes were immobilized on the slide to fabricate bead array through magnetic field. The bead array was hybridized with the corresponding allele-specific tag probes for each locus, and a pair of given universal detectors were applied to these markers analysis. Using bead array, all samples can be analyzed in one hybridization chamber which lowers the cost of the assay. 100 High-throughput methods for SNP genotyping have also been used in a large number of samples in large studies in China. In these studies, gel-based microarray combined with universal dual-color hybridization was used by Chinese researchers. [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] Nanotechnology extends the limits of molecular diagnostics to the nanoscale. Nanotechnology-on-a-chip is one more dimension of microfluidic/lab-on-a-chip technology. The Nano Chip system uses electronically accelerated hybridization under minimal salt conditions, potentially avoiding problems with DNA conformation and secondary structures, whereas most sequencing and primer extension technologies require high-salt conditions. The hybridization is not only accelerated by an electrical potential, but (after switching) this potential can be used to considerably enhance the specificity. The ability to perform all the steps of the biological assay on a single selfcontained microchip promises significant advantages in terms of speed, cost, sample/reagent consumption, contamination, efficiency and automation (including parallel sample processing). 112 Accordingly, this DNA microchip technology offers an enormous potential for rapid multiplex analysis of nucleic acid samples, including the diagnosis of genetic diseases, detection of infectious agents, measurements of differential gene expression, drug screening or forensic analysis. Such use of DNA microarrays is thus revolutionizing many aspects of genetic analysis. 113 Such hybridization chips are fabricated from glass, silicon or plastic supports, and comprise thousands of 10-100 m reaction zones onto which individual oligonucleotides have been deposited. The exact number of probes varies in accordance with the application. The actual construction of gene chips involves the immobilization or synthesis of an array of DNA probes on a solid support. The detection of the DNA hybridization (at the individual spots) relies on the signal generated by the binding event. Unlike individual biosensors, scanning or imaging the chip surface is essential for obtaining the complete hybridization pattern. Fluorescence imaging and mass spectroscopy are commonly used for such 'reading' of the chips. Bioinformatics tools are used to relate the complexity of the data into useful information. The Gene Chip system of the array pioneer, Affymetrix (Santa Clara, CA), provides the sequence information by hybridization with a set of target DNA fragments prepared from one or more genes of interest. The company has a number of Gene Chips for screening for breast cancer, for detecting mutations in the HIV genome and in the p53 tumor-suppressor gene, or for identifying bacterial pathogens. 114 DNA microarrays offer great promise for monitoring gene expression in humans.
Nanoparticle Protein Chip
A sensitive technique has been developed for optical detection of nanogold particle-labeled molecules on protein microarray by applying the surface plasmon resonance and specific molecular binding using rolling circles amplification. The protein chip has been developed incorporating with signal amplification technology based on gold nanoparticles (AuNPs) and microfluidic technology. The chip was a reversed phase one that deposited the target proteins directly onto chip surface. 115 Protein chips, based on protein-binding silicananoparticles, are in development at Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB (Stuttgart, Germany). The surface of a silica-nanoparticle with a diameter of less than 100 nm can be configured with many different capture proteins. The particles configured in this way are then applied to silicon carriers in thin, even layers. After contact is made with a sample, the chips can be analyzed using state-of-the-art mass spectrometry (MS)-Matrix-Assisted Laser Desorption/Ionization (MALDI)-time-of-flight (TOF) MS.
Detection of miRNA Using Nanoparticles
Wanunu et al. 116 have recently presented a platform for the rapid electronic detection of probe-hybridized microRNAs from cellular RNA. In their work, target microRNA is first hybridized to a probe. This probe: microRNA duplex is then enriched through binding to the viral protein p19. Finally, the abundance of the duplex is quantified using a nanopore. Reducing the thickness of the membrane containing the nanopore to 6 nm leads to increased signal amplitudes from biomolecules, and reducing the diameter of the nanopore to 3 nm allows the detection and discrimination of small nucleic acids based on differences in their physical dimensions. They have demonstrated the potential of this approach by detecting picogram levels of a liverspecific miRNA from rat liver RNA.
RNA Sequencing
The application of RNA sequencing (RNA-seq) is fast superseding microarray technology by providing a superior digital readout whilst also enabling discovery of novel splice forms, transcripts and RNA-editing. 117 Quantitative gene expression data derived from RNA-seq has been shown to be comparable to that of microarrays but has better dynamic range and lower detection limit for lowly expressed transcripts. 118 Methods for analyzing differential expression from RNA-seq data, however, are still being resolved and are reminiscent of the initial issues encountered for normalization and statistical analysis of microarray data. 119 Clinical applications of gene expression microarrays as a cancer diagnostic and prognostic tool have been demonstrated with examples including identification of tissue of origin for cancer of unknown primary and prediction of recurrence in early stage breast and colorectal cancer. [120] [121] [122] Whilst it remains to be seen whether RNA-seq could replace microarrays or quantitative PCR as a clinical assay, it would seem intuitive to think that this could occur if the technology becomes cheaper and more robust.
Gao and Yang 123 and Wang et al. 124 have also recently developed a nanoparticle-based assay that can detect the trace amounts of miRNAs found in cells. Their new assay uses reactive nanoparticles made of osmium oxide. These nanoparticles will oxidize a chemical known as hydrazine, and if the nanoparticles are bound to an electrode, the oxidation of hydrazine generates a sharp, sensitive electrical signal registered by the electrode. Their method also demonstrates a great application potential for disease diagnosis relying on miRNA biomarkers, or in small RNA expression profiling for new target discovery and functional study.
NEXT-GENERATION SEQUENCING COMPARED WITH MICROARRAYS
Currently, global analysis of gene expression relies largely on hybridization-based platforms such as microarrays, which are routinely used for determining relative expression levels or changes in gene expression between different biological conditions. Unlike hybridization data, which consist of continuous signals, sequence census data are made of absolute numbers of reads. The countable, almost digital, nature of these results makes them highly suitable for the analysis of gene expression levels. Applying sequence census approaches to cDNAs (RNA Seq), we can therefore estimate the relative abundance of given transcripts by counting the number of times they are hit by sequence reads. Recent studies have shown that, indeed, scores based on the number of sequence reads hitting a transcript, or on the average number of hits per base and per transcript, provide accurate measurements of relative RNA levels. 125 In addition, unlike microarray data, which are affected by the dynamic range of the scanner, sequence data have a linear dynamic range only limited by the sequencing depth. In addition, and unlike hybridization based techniques, sequencing-based approaches produce little or no noise, allowing detection of even very minimally expressed transcripts. In the short term, however, the costs and amount of data produced make it unlikely that sequence census approaches will completely replace microarrays as the routine tool for expression profiling.
As already mentioned, microarray design requires a priori knowledge of the genome or genomic features. This directly affects array effectiveness in cases of incomplete, incorrect, or outdated genome annotations. A major obstacle in microarray analysis is cross hybridization between similar sequences. This restricts microarray analysis to the non-repetitive fraction of genomes and complicates analysis of related genes (or features); alternatively spliced transcripts, allelic gene variants, and SNPs.
NGS-based approaches offer remedies to the above problems: (i) Knowledge of genome annotation is helpful, but not required. In fact, data from next generation platforms has recently been assembled into a genome de novo.
(ii) The fact that material is directly sequenced and not interrogated by hybridization to user defined sequences removes experimental bias and cross-hybridization issues from the analysis. Since NGS offers single-nucleotide resolution, one can monitor expression from gene alleles that differ in as little as one nucleotide of sequence. As the length of NGS reads increases, so too will the ability to probe repetitive regions of the genome. (iii) Quantification of signal from sequence-based approaches is based on counting sequence tags rather than relative measures between samples: the result is unlimited fully-quantitative dynamic range of signal. NGS approaches are equally adept at detecting changes in rare and highly expressed sequences present in the same sample. (iv) In terms of experimentation, nano grams of material are sufficient for NGS, reducing or eliminating the reliance on PCR amplification of material. (v) Since data is collected genome-wide, investigators can simultaneously monitor RNAs from, or factor binding to, all known and undefined genomic features (i.e., promoters, exons, non-coding RNAs (ncRNA) and enhancers).
Because all next generation platforms have the same data output (a tally of sequences) it is hoped that the reproducibility of experimentation, and simplicity of bioinformatics analysis, will be much improved over a variety of microarray platforms with unique oligonucleotide probes and hybridization conditions. 126 
WHEN TO SWITCH FROM MICROARRAYS TO NGS
Researchers facing such choices need to look into a few key areas, such as research goals (e.g., discovery vs. profiling), access to technology, maturity of applications, cost per sample, and desired throughput. These key aspects for the primary genomic applications are addressed separately below. For some applications, such as chromatin immunoprecipitation, the transition to NGS is nearly complete. 127 
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were among the first to be switched from arrays (ChIP-chip) to sequencing (ChIP-Seq), as the new NGS technology provides much better peak resolution. The transition was swift as this application is less demanding in terms of what is needed from the sequencing platforms-only a small number of short reads are required. The rapid drop in the cost of NGS has accelerated the transition. 12 
Gene Expression
Researchers have been eager to use NGS for gene expression experiments as it provides a more detailed look at the transcriptome. Arrays suffer from fundamental 'design bias'-they only return results from those regions for which probes have been designed. Consequently, arrays are only as good as the databases from which they are designed. Conversely, the various RNA-Seq methods cover all aspects of the transcriptome without any a priori knowledge of it, allowing for the analysis of such things as novel transcripts, splice junctions and noncoding RNAs. Despite the technical advantages of RNA-Seq, microarrays remain popular for two primary reasons. One, their longtime use as a genomics tool means many researchers are very comfortable using them-sample labeling; array handling and data analysis methods are tried and true. Two, despite NGS advancements, expression arrays are still cheaper and easier when processing large numbers of samples (e.g., hundreds to thousands). 127 
Genotyping
For genotyping studies, microarrays are still widely adopted as they are substantially less expensive than NGS and much more conducive to processing thousands of samples required for typical genome-wide associations studies (GWAS). Unlike gene expression, array-based SNP assays are much less prone to design bias. However, as microarrays are limited in the number of SNPs they can contain, they tend to focus more on relatively common variants. Some researchers feel more emphasis should be placed on SNPs with lower minor allele frequency (MAF). Although newer arrays are being designed with lower MAFs in mind, many researchers are starting to gravitate towards sequencing as it can capture both common and rare variants. However, the major stumbling block is the cost of whole genome sequencing (WGS). 127 
Methylation
The choice is more complicated with methylation projects. While NGS unquestionably provides a more complete picture of the methylome, whole genome methods are still quite expensive. To reduce costs and increase throughput, some researchers are using targeted methods, which only look at a portion of the methylome. However, microarrays remain a popular choice as their use reduces the cost and increases throughput even further. Because details of exactly how methylation impacts the genome and transcriptome are still being investigated, many researchers find a combination of both technologies best fits their needs-NGS for discovery and microarrays for rapid profiling. 127 
Diagnostics
For the diagnostics market, the transition from microarrays to sequencing has been much slower. Microarrays offer simpler data analysis, as it is known ahead of time exactly what kind of data will be returned. With NGS, there's always the possibility of revealing something new and unexpected. While that can be really useful in a research environment, clinicians generally aren't prepared for this extra information. But the power and potential cost savings of NGS-based diagnostics is alluring, leading to their cautious adoption for certain tests such as non-invasive prenatal testing. 127 NGS platforms have been used for transcriptome profiling, miRNA profiling, DNA-protein interaction studies, using chromatin immunoprecipitation (ChIP), and DNA methylation studies, thus challenging the use of microarrays. Researchers considering replacing microarrays with sequencing platforms should therefore be aware of the advantages and disadvantages associated with both methods. 128 
CONCLUSION AND FUTURE PERSPECTIVES
Next-generation sequencing technologies, microarrays and nanotechnology have had an enormous impact on biomedical research within a short time frame. This impact appears certain to increase further as many institutions are now acquiring these prevailing new technologies. Beyond conventional sampling of genomic content, wide-ranging applications are rapidly evolving for nextgeneration sequencing. At this time, the huge amount of data generated by next generation sequencing and microarrays creates an informatics challenge. The establishment of routine data analysis methods, together with future decreases in sequencing costs and increases in the numbers and lengths of sequence reads, will help to unleash the full potential of next-generation sequencing. While dropping prices and maturing technology are causing NGS and microarrays to make headway in becoming technologies of choice for a wide range of applications, the transition away from microarrays is a long and varied one. Different applications have different requirements, so researchers need to carefully weigh their options when making the choice to
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switch to a new technology or platform. In this regard, nanotechnology should also be considered in making choices, because it has been applied both in DNA sequencing, genotyping and molecular detection of pathogens and cancer. Regardless of which technology they choose, genomic researchers have never had more options.
